EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immunogenicity of red cell alloantigens in the Japanese population

Mao Watanabe, Hitoshi Ohto, Christopher A Tormey, Hiroyasu Yasuda, Nozomi Takano, Keiji Minakawa, Satoshi Ono, Maiko Yamada-Abe, Hiroe Suzuki, Akiko Sugawara, Kinuyo Kawabata, Kenneth E Nollet, Kazuhiko Ikeda

International Journal of Blood Transfusion and Immunohematology · 2020

DOI: 10.5348/100053z02mw2020ra ↗
AbstractBibliografische Angaben

Abstract

Aims: To elucidate transfusion-related blood group antigen immunogenicity among Japanese, a retrospective single center study was done. Methods: For 49,884 transfusion recipients from late 2006 to early 2018, antibodies were tested with two techniques: saline immediate spin test and polyethylene glycol-enhanced indirect antiglobulin test. From male recipients with an average of 4.2 donor exposures, we calculated the immunogenicity of blood group alloantigens with a mathematical model. Results: Indirect antiglobulin test detected 638 alloantibodies, 391 (1.53%) among 25,563 women and 247 (1.02%) among 24,321 men. Anti-E (489.1 per 100,000), followed by anti-Lea (238.6 per 100,000) and anti-Fyb (100.2 per 100,000) were most frequently found in the whole. Immunogenicity calculations among male recipients based on 4-donor exposure revealed Jra (67.4 per 1000, 95% CI: 1.7–323.3) as the possibly highest potency antigen, followed by: Lea (23.5 per 1000, 95% CI: 17.4–29.6), Dib (20.1 per 1000, 95% CI: 0.5–109.3), E (11.9 per 1000, 95% CI: 9.4–14.4), and Jka (5.7 per 1000, 95% CI: 1.7–9.6) among Japanese male recipients. Conclusion: Jra and Diego blood group antigens might be highly immunogenic in the Japanese population, but more recipients would need to be investigated to establish statistical significance.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →